CI

At a glance

ClinicalIndex Comparison Record
Early Ph 1Completed· 14 enrolled
Drug / intervention
Pioglitazone 30 mgdrug
Likely dose
Pioglitazone 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04300127
NCT04300127Early Ph 1Completed
CompareCT.gov

Pioglitazone for the Treatment of Idiopathic Gastroparesis (PIOGAS Study)

Johns Hopkins University·interventional·Posted Mar 9, 2020·Updated Apr 30, 2025

In Brief

A Early Phase 1 clinical trial evaluating Pioglitazone 30 mg for Gastroparesis. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The principal objective of this pilot study will be to evaluate whether 8 weeks of treatment of pioglitazone will improve symptoms as measured by the Gastrointestinal Symptom Index (GCSI) in patients with Idiopathic Gastroparesis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastroparesis
CountriesUnited States
Collaborators--

Timeline

Early Ph 1CompletedFinished
2020202120222023202420252026
First PostedMar 9, 2020
Enrollment StartOct 24, 2019
Primary CompletionMar 15, 2025
Study CompletionMar 18, 2025
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 6.3 years ago

Interventions

Pioglitazone 30 mgdrug

Patients will received 30 mg of Pioglitazone once a day for 8 weeks